Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | GLP1R | P43220 | 8/20 | 0.56 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | NPY4R | P50391 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
| ▸ | GCGR | P47871 | 1/20 | 0.54 |
| ▸ | GIPR | P48546 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30576953 | 0.90 | KEAP1 (0.60) | KEAP1GLP1RCXCL8CXCR4NPY1R | |
| SCHEMBL5710842 | 0.85 | CXCR4 (0.60) | KEAP1GLP1RCXCR4NPY1RNPY2R | |
| SCHEMBL30320533 | 0.85 | CXCR4 (0.60) | KEAP1GLP1RCXCR4NPY1RNPY2R | |
| SCHEMBL31182988 | 0.85 | NPY2R (0.71) | KEAP1GLP1RNPY1RNPY2RNPY4R | |
| SCHEMBL31182837 | 0.85 | CXCR4 (0.67) | KEAP1GLP1RCXCR4NPY1RNPY2R | |
| SCHEMBL31182989 | 0.85 | NPY1R (0.67) | GLP1RCXCL8NPY1RNPY2RNPY4R | |
| SCHEMBL30658222 | 0.85 | NPY1R (0.69) | GLP1RCXCR4NPY1RNPY2RNPY4R | |
| SCHEMBL31575690 | 0.85 | CXCR4 (0.63) | GLP1RCXCR4NPY1RNPY2RNPY4R | |
| SCHEMBL31182795 | 0.85 | CXCL8 (0.63) | KEAP1GLP1RCXCL8NPY1RNPY2R | |
| SCHEMBL30690109 | 0.84 | CXCL8 (0.58) | CXCL8CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064834-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (IE) | 2025-02-27 | — | — | US | disclosed |
| EP-4475853-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | Prendergast, Patrick T. (IE) | 2024-12-18 | — | — | EP | disclosed |
| CN-118804754-A | Compositions and methods for treating and preventing diseases using tirapazad salts | 帕特里克·T·普伦德加斯特 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023154647-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (IE) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064834-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | CYP24A1, IL23R, IL17A | KEAP1 3244/4885GLP1R 3610/4885CXCL8 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.